Please assess the completion status of the following clinical trial:

Trial Title: A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically documented invasive epithelial ovarian, extraovarian, fallopian tube or endometrial carcinoma.~* Patients must have persistent or recurrent disease after standard debulking/staging surgery and conventional therapy.~* Patients must have evidence of intraabdominal disease; disease may be measurable or nonmeasurable.~* Patients must have a GOG performance status of 0, 1, or 2, and have a life expectancy of greater than 3 months.~* Patients must have adequate hematologic, renal, and hepatic function defined as:~  * WBC \> 3,000 ul~ * Granulocytes \> 1,500 ul~ * Platelets \> 100,000~ * Creatinine clearance \> 80 mg/dl or serum creatinine \> 2.0~ * Serum transaminases \< 2.5 x upper limits of normal~ * Normal serum bilirubin~ * PT/PTT/INR \< 1.5 x institutional ULN~ * O2 saturation \> or = 92 %~* Patients must be 19 years or older and must have signed informed consent~Exclusion Criteria:~* Patients with epithelial tumors of low malignant potential, stromal tumors and germ cell tumors of the ovary are ineligible to participate in the study.~* Patients with the only site of disease located beyond the abdominal cavity are ineligible to participate in the study.~* Patients who are pregnant or lactating are ineligible to participate in the study.~* Patients with a GOG performance status of 3 or 4 are ineligible to participate in the study.~* Patients with active heart disease (characterized by angina, unstable arrhythmia, congestive heart failure or EF \< 55%, pulmonary hyper- tension, active or chronic debilitating pulmonary disease(i.e., active pneumonia, severe COPD, pulmonary edema, O2 saturation \< 92%), or coagulation disorders (i.e. bleeding disorders, or on therapeutic anti- coagulants)

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gene therapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).